EAP | Early Access Programs

Q: EAP | Early Access Programs

Early Access Programs for innovative medicines Early Access Programs (EAPs) are schemes established by health authorities or pharmaceutical companies to provide patients with innovative treatments before marketing authorisation. EAPs typically target serious or rare diseases and address urgent unmet medical needs. EAPs often include structured clinical follow-up and contribute to generating real-world evidence, which supports regulatory submissions and facilitates earlier patient access to promising therapies.

Early Access Programs for innovative medicines

Early Access Programs (EAPs) are schemes established by health authorities or pharmaceutical companies to provide patients with innovative treatments before marketing authorisation.

EAPs typically target serious or rare diseases and address urgent unmet medical needs.

EAPs often include structured clinical follow-up and contribute to generating real-world evidence, which supports regulatory submissions and facilitates earlier patient access to promising therapies.